![Neurocrine Biosciences, Inc. logo](/logos/NBIX.webp)
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
Overview | Financials
Company Name | Neurocrine Biosciences, Inc. |
Symbol | NBIX |
Currency | USD |
Price | 120.17 |
Market Cap | 12,134,285,920 |
Dividend Yield | 0% |
52-week-range | 103.63 - 157.98 |
Industry | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Dr. Kevin C. Gorman Ph.D. |
Website | https://www.neurocrine.com |
An error occurred while fetching data.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD